TEDG reported around $10 million in vaccines sales last fiscal year, with $1.5 million in net income profit. Based on other biotech 'bird flu' plays within the sector, we feel TEDG should have a fair market cap value of at least $120 million. This still would only give TEDG a price/sales ratio of 12 as compared to others in the sector ranging from 17 to 1,060 times sales.
The market cap for stocks within the bird flu sector range from $72 million up to $335 million, with TEDG only having a current market cap of $35 million. We feel $120 million market cap for a Chinese vaccine biotech generating $10 million in vaccine sales, and a net profit of $1.5 million should fairly reflect a $120 million in market cap value, at least. Thus, with 82 million shares outstanding TEDG should be trading around a fair value of $1.46 a share in the open market.
($120 million market cap / 82 million outstanding = $1.46 a share)
Ranked by market caps dated May 02, 2006. NOTE: TEDG currently has one of lowest market caps at $35 million for this sector group.
AVII = $335 million NVAX = $311 million GNBT = $275 million HEB = $204 million VICL = $203 million SVA = $169 million STTK = $72 million TEDG = $35 million
RANK BY PRICE/SALES RATIO
Ranked by price to sales ratio dated May 02, 2006. P/S ratio tells investors how many times sales a stock is currently trading at.
GNBT = 1,060 HEB = 192 AVII = 70 NVAX = 43 SVA = 25 VICL = 17 TEDG = 4 STTK = NA
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.